Coloplast prepares big study of main asset from million-dollar acquisition

After the acquisition of Nine Continents Medical, Coloplast is getting ready to try out the US-based urology firm's main asset against over-active bladder disorder (OAB) in a big clinical trial in the US. The company is expecting to release the results as soon as next year, and hopes for a potential launch in 2024-2025.
Photo: Coloplast / PR
Photo: Coloplast / PR
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN

Coloplast is taking its first step into a new segment of the urology area. The medtech company has just made the final preparations for an extensive clinical study with the company's solution, a "tibial nerve stimulator," for over-active bladder disorder (OAB), the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading